Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 7, 2008, Pages 795-798

  Mark, Tomer ^a   Stern, Jessica ^a   Furst, Jessica R ^a   Jayabalan, David ^a   Zafar, Faiza ^a   LaRow, April ^a   Pearse, Roger N ^a   Harpel, John ^a   Shore, Tsiporah ^a   Schuster, Michael W ^a   Leonard, John P ^a   Christos, Paul J ^a   Coleman, Morton ^a   Niesvizky, Ruben ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Autologous stem cell transplantation; Cyclophosphamide; Lenalidomide; Multiple myeloma; Stem cell mobilization

Indexed keywords

ACETYLSALICYLIC ACID; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; OMEPRAZOLE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; STEM CELL MOBILIZATION;

AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATINICS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REMISSION INDUCTION; STEM CELLS; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 44649202066     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.04.008     Document Type: Article

References (18)

1. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 21 (2007) 2035-2042
2. Koreth J., Cutler C.S., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 13 (2007) 183-196
3. Anderson K.C., and Vesole D.H. Stem cell transplant for first relapse from the multiple myeloma research foundation. Oncology (Williston Park) 20 (2006) 1818 1820-1821, 1825-1826
4. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
5. Barlogie B., Tricot G.J., van Rhee F., et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135 (2006) 158-164
6. Weber D.M., Chen C., Niesvizky R., et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007) 2133-2142
7. Dimopoulos M., Spencer A., Attal M., et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007) 2123-2132
8. Niesvizky R., Jayabalan D.S., Christos P.J., et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 111 (2008) 1101-1109
9. Mazumder A., Kaufmann J., Niesvizky R., Lonial S., Vesole D., and Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia (2007) Nov 22 [Epub ahead of print]
10. Paripati H., Stewart A.K., Cabou S., et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia (2008) Jan 24 [Epub ahead of print]
11. Durie B.G., Harousseau J.L., Miguel J.S., et al. International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia 20 (2006) 1467-1473
12. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335 (1996) 91-97
13. Abdelkefi A., Ladeb S., Torjman L., et al. on behalf of the Tunisian Multiple Myeloma Study Group. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111 (2008) 1805-1810
14. Dingli D., Nowakowski G.S., Dispenzieri A., et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 6 (2006) 384-388
15. Desikan K.R., Barlogie B., Jagannath S., et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16 (1998) 1547-1553
16. Niesvizky R., Naib T., Christos P.J., et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 138 (2007) 640-643
17. Rajkumar S.V., Hayman S.R., Lacy M.Q., et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106 (2005) 4050-4053
18. Lacy M.Q., Gertz M.A., Dispenzieri A., et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184